Biological products and biosimilars follow a different Thai FDA pathway from small-molecule drugs. The dossier requirements, manufacturing standards, and post-approval obligations differ in ways that matter before the first file is submitted.
Thailand does not have a standalone biologics act. Biological products are regulated under the Drug Act B.E. 2510 (1967) and its B.E. 2562 (2019) amendment, and they are classified as drugs for the purposes of Thai FDA registration. The practical consequence is that biologics enter the drug registration pathway, not a parallel biologics-specific system.
Thai FDA recognizes biologics as products derived from or manufactured in living systems, including cells, tissues, or microorganisms, and which cannot be fully characterized using conventional physicochemical methods alone. The categories covered include recombinant proteins, monoclonal antibodies, therapeutic vaccines, blood-derived products, gene therapy products, and advanced therapy medicinal products.
The distinction between a biologic and a large-molecule conventional drug is not always obvious at the dossier stage. Thai FDA determines product category on a case-by-case basis, and the classification affects the quality dossier structure, GMP requirements, and post-approval surveillance obligations. Misclassifying a complex protein as a conventional drug affects every downstream step and can force resubmission once identified.
Originator biologics register under the New Drug category. All new drugs in Thailand carry a mandatory Safety Monitoring Program (SMP), which restricts dispensing to hospitals for a defined post-approval period before full registration is granted. For most biologics, the minimum SMP duration is 2 years.
Biosimilars register under the New Generic category but face additional comparative requirements that do not apply to small-molecule generics. A biosimilar applicant must demonstrate similarity to a reference biologic through a stepwise evidence package, not simply through standard bioequivalence data.
Products approved by a recognized stringent regulatory authority, including US FDA, EMA, or those holding WHO prequalification, may qualify for a reduced SMP period if the supporting dossier includes an established post-market safety record from the reference jurisdiction. Thai FDA evaluates these applications on the completeness of the comparative safety data submitted, not solely on the foreign approval status.
The quality section of a biologics dossier follows the ICH Q5 series of guidelines, not ACTD Part III, which applies to small-molecule drugs. This distinction matters because the analytical and manufacturing documentation for biologics must address the unique complexity of living-system manufacture.
Covers testing and clearance studies for adventitious viral agents in products derived from cell lines or human or animal sources. Thai FDA expects a viral safety evaluation report addressing both testing of source materials and process validation for viral clearance steps.
Applies to products expressed using recombinant DNA technology. The dossier must characterize the expression construct, cell banks, and the genetic stability of the producing cell line across the expected production life.
Stability requirements for biologics differ from those for small molecules, particularly regarding protein degradation pathways. Real-time stability data under the proposed storage condition, along with forced degradation studies, must be included.
Covers characterization and testing of cell substrates used in manufacture. Master and working cell bank qualification must be documented, including identity, purity, and characterization of the producing cell line.
Applies when manufacturing changes occur that could affect the product's quality, safety, or efficacy. For biosimilar applications, Q5E principles underpin the comparative analytical package required to support the similarity claim.
Administrative and labeling documentation, forming ACTD Part I, is still required in Thai and follows the same structure as for small-molecule drugs. The quality, nonclinical, and clinical sections use the ICH Q5 and relevant S-series and E-series guidelines as the applicable framework.
A biosimilar application must demonstrate that the proposed product is highly similar to a reference biologic, with no clinically meaningful differences in safety, purity, or potency. Thai FDA follows a stepwise comparability approach consistent with WHO guidelines on evaluation of similar biotherapeutic products.
The first step requires comprehensive side-by-side analytical characterization of the biosimilar and reference product. State-of-the-art methods must be used to characterize primary and higher-order structure, glycosylation profiles, potency, and degradation products. Any identified differences must be assessed for clinical relevance.
In vitro studies demonstrating functional similarity are typically required, including receptor binding and cell-based potency assays. In vivo animal studies may be waived if the analytical similarity package is sufficiently robust, but this must be justified within the dossier.
Comparative pharmacokinetic studies are required to confirm that the biosimilar and reference product behave similarly in humans. These studies are typically conducted in healthy volunteers for non-cytotoxic products. Pharmacodynamic endpoints are included where a validated biomarker exists.
A confirmatory clinical study is typically required unless the totality of evidence from earlier steps is sufficient to support a waiver. The study population, endpoint, and design must be discussed with Thai FDA in advance of commencement.
Anti-drug antibody (ADA) data from clinical studies must be included and compared between the biosimilar and reference product. Post-market immunogenicity monitoring must be proposed as part of the pharmacovigilance plan submitted with the registration dossier.
Overseas biologics manufacturers must hold a current WHO GMP certificate or an equivalent from a recognized regulatory authority such as EMA or US FDA. Thai FDA may conduct its own GMP inspection for certain high-risk biologic categories, including gene therapy products and blood-derived products, regardless of existing certification.
GMP accreditation for biologics is product-specific and valid for 3 years, consistent with requirements for small-molecule drugs. The scope of the GMP certificate must cover all manufacturing steps performed at that site, including cell culture, purification, filling, and final release testing. A certificate that does not cover the relevant steps will fail screening review.
Cold-chain validation documentation is required for temperature-sensitive biologics. The dossier must include data demonstrating that the proposed storage and transport conditions maintain product quality from the manufacturing site to the patient. The import and distribution logistics plan must be consistent with those validated conditions.
Marketing authorization holders for biological products carry post-approval obligations that go beyond those for small molecules. Periodic Safety Update Reports (PSURs) are required at 6-month intervals during the SMP period and annually thereafter. The pharmacovigilance plan submitted with the registration dossier must be maintained and updated as the safety profile evolves with commercial experience.
Immunogenicity surveillance is a specific ongoing requirement for biologics and biosimilars. The LAR must operate a post-market program to detect and evaluate anti-drug antibody formation, including a plan for reporting unexpected immunogenicity signals to Thai FDA within 15 days of identification.
Manufacturing process changes after approval require a comparability exercise under ICH Q5E principles before a variation application is filed. The extent of the comparability data depends on the nature and scale of the change. Process changes that affect product quality attributes critical to safety or efficacy cannot be implemented under a minor variation; they require prior Thai FDA approval before implementation begins.
VeroPharma Group supports biologics and biosimilar registration in Thailand from initial pathway determination through dossier preparation and Thai FDA correspondence. The regulatory framework for biologics is more complex than for small molecules, and the consequences of a dossier submitted under the wrong pathway or missing the ICH Q5 structural requirements are measured in years of delay, not weeks.
We advise on classification, SMP strategy, reference product selection for biosimilars, and the design of comparability packages before work begins. If a timeline or comparability data package is not sufficient to support the application, we say so at the planning stage.